How is oxytocin taken, according to sources?
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Yatawara and colleagues, 20162 | 12 IU morning and night (24 IU a day) vs placebo nasal spray, crossover; week 1 stepped from 3 IU up by 3 IU every 2 days to 12 IU morning and night on day 7, then 6 IU per spray, one spray per nostril, morning and night, in weeks 2 to 5 | Thirty-one children with autism aged 3 to 8 | 5 weeks per arm, 4-week washout |
| SOARS-B, Sikich and colleagues3 | Flexible dose vs placebo: started at 8 IU each morning, target 48 IU a day as 24 IU twice daily, begun at week 8; once the target had been kept for 7 weeks, the dose could rise by 16 IU every 4 weeks to a maximal total daily dose of 80 IU | 290 children and adolescents aged 3 to 17 with autism spectrum disorder, randomised 1:1; 277 analysed | 24 weeks |
The Pitocin label gives oxytocin by intravenous infusion or intramuscular injection, in labour and after delivery; nasal doses come from autism trials, which gave children aged 3 to 8 12 IU morning and night (Yatawara and colleagues, 2016) or started children and adolescents aged 3 to 17 at 8 IU each morning with a target of 24 IU twice daily (SOARS-B).123
Nasal oxytocin doses in trials
The table is set at the top of the page
Nasal doses come from trials, not a label: searches of DailyMed and ClinicalTrials.gov turned up no US label for an oxytocin nasal spray. Their sprays were 8 IU and 24 IU per 0.1 ml, against 4 IU per 0.1 ml for the Novartis Syntocinon product, on which they note a 24 IU dose needs 0.6 ml.3
Striepens and colleagues gave adult male volunteers who were undergoing diagnostic lumbar puncture 24 IU as 3 puffs per nostril of 4 IU from Syntocinon spray, 11 on oxytocin and 4 on placebo.4 They say the majority of previous studies using single-dose nasal oxytocin used the same 24 IU dose.4 MacDonald and colleagues' 2011 systematic review of 38 randomised controlled trials, with N=1529 participants, reports doses from 18 to 40 IU, mainly single doses, ranging up to 182 administrations.5 Shafer and colleagues (2025) gave 24 healthy adults 100 μg of nasal oxytocin (TNX-1900, 25 μg per spray) and measured nasal bioavailability of 0.7%, with substantial subject-to-subject variability.6
What the injection labels give
The Pitocin label gives 1-mL single-dose vials of 10 units and a 10 mL multiple-dose vial of 10 units per mL.1 The Fresenius Kabi label also gives each mL as 10 USP Oxytocin Units.7 The Pitocin routes are intravenous infusion or intramuscular injection, for induction or stimulation of labour and, after delivery, to produce uterine contractions in the third stage of labour and to control postpartum bleeding; for induction or stimulation of labour, the label calls intravenous drip the only acceptable parenteral method.1 For control of postpartum uterine bleeding, the Pitocin label gives one mL, Ten (10) units, intramuscularly after delivery of the placenta.1
For induction or stimulation of labour, the Pitocin label makes its standard infusion by adding one 1-mL vial of 10 units to 1000 mL of 0.9% sodium chloride or Ringer's lactate, giving 10 milliunits per mL.1 It gives an initial infusion dose of 0.5 to 1 mU/min, raised at 30 to 60 minute intervals in steps of 1 to 2 mU/min until the desired contraction pattern has been established.1 It says the dosage is determined by uterine response, individualized and started at a very low level.1 No label gives a way to mix a powder for self-injection, and the Grindeks oxytocin powder listing is for manufacturing, processing and repackaging.8
Subcutaneous oxytocin in one trial
In a two-session crossover trial run from January 2023 to July 2023, Albinni and colleagues gave 20 healthy adults a subcutaneous injection in the forearm of 4 mcg in 2 mL of oxytocin (Pitocin from Fresenius Kabi) or saline placebo, and eighteen completed full procedures.9 The report gives no adverse or unintended effects of oxytocin.9 It used a single injection per session, and no repeated-dose schedule turned up. No label gives oxytocin in mcg; the Shafer pharmacokinetic study describes Fresenius Kabi oxytocin injection, USP, as 16.7 μg ml−1, a product whose label gives each mL as 10 USP Oxytocin Units, and the sources give no general conversion between mcg and units.67
Storage
The Pitocin label gives 20° to 25°C, and the Fresenius Kabi label gives 20° to 25°C and not to freeze.17 Neither label gives a storage condition or time after dilution or mixing; the Fresenius Kabi label adds "Discard unused portion."7
Frequently asked questions
What side effects and warnings does the oxytocin label give?
Is there an oxytocin cycle?
No label or human trial describes a cycle of oxytocin for non-obstetric self-use.
What do Milligram users log for oxytocin?
No logged share for oxytocin is shown.
- OxytocinThe oxytocin compound page.
- Cognitive and sleep peptidesThe class oxytocin is listed under.
- Mixing guideHow a vial is mixed and read on a syringe.
- Semax dosageWhat sources say about semax doses.
- How to take selankWhat sources say about selank.
- DSIP dosageWhat sources say about DSIP doses.
- Units and dosingTurning a dose into syringe units.
References
- Par Health USA, LLC. Pitocin ® (Oxytocin Injection, USP) Synthetic. 2026. dailymed.nlm.nih.gov
- Mol Psychiatry. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. 2015. pmc.ncbi.nlm.nih.gov
- N Engl J Med. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. 2021. pmc.ncbi.nlm.nih.gov
- Sci Rep. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. 2013. pmc.ncbi.nlm.nih.gov
- PubMed. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. 2011. pubmed.ncbi.nlm.nih.gov
- Br J Anaesth. Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults. pmc.ncbi.nlm.nih.gov
- Fresenius Kabi USA, LLC. Oxytocin Injection, USP. 2026. dailymed.nlm.nih.gov
- Grindeks. Oxytocin (High Potency Powder). 2025. dailymed.nlm.nih.gov
- J Pain. Subcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial. 2024. pmc.ncbi.nlm.nih.gov